Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prime Medicine, Inc. SEC filings document the biotechnology company's financial results, pipeline disclosures, governance matters and material events tied to its Prime Editing programs. Recent Form 8-K filings include Item 2.02 results releases, Regulation FD corporate presentations and Item 5.02 executive appointment disclosures, with exhibits summarizing business highlights for PM577 in Wilson Disease, PM647 in Alpha-1 Antitrypsin Deficiency and PM359 in chronic granulomatous disease.
Proxy materials disclose annual meeting matters, director elections, auditor ratification, executive compensation and equity-plan information. Together, the filings provide formal records of PRME's public-company governance, disclosure controls, capital and compensation arrangements, and regulatory-development communications for its genetic-medicine pipeline.
Prime Medicine, Inc. reported collaboration revenue of $1.15 million in the quarter ended June 30, 2026 and a net loss of $42.1 million, or $0.24 per share. For the first half of 2026, revenue was $2.0 million and net loss narrowed to $91.2 million from $104.5 million a year earlier, mainly due to lower research and development spending.
Cash, cash equivalents and short‑term investments totaled $95.1 million as of June 30, 2026, with stockholders’ equity at $39.8 million. Management concludes that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months without additional financing and highlights its at‑the‑market equity program and other potential transactions, while expecting existing cash to fund operations into 2027.
Prime Medicine advanced its Prime Editing pipeline: regulators cleared a CTA in New Zealand and an FDA IND for Wilson disease candidate PM577a, and an IND/CTA filing for AATD candidate PM647 is planned for the third quarter of 2026. CGD program PM359 received FDA RMAT designation, with a planned BLA submission in the first half of 2027. An arbitration tribunal also confirmed PM647 is within the company’s “Field” under its Beam collaboration and denied Beam’s requests for damages and injunctive relief.
Prime Medicine, Inc. reported second quarter 2026 results and pipeline updates. Collaboration revenue was modest while operating expenses declined, with research and development at $33.4 million and general and administrative at $11.0 million. Net loss narrowed to $42.1 million and cash, cash equivalents, investments and restricted cash totaled $108.8 million as of June 30, 2026, which the company expects will fund operations into 2027.
Programmatically, IND and CTA clearances in the United States and New Zealand established a global Phase 1/2 program for PM577a in Wilson disease, with initial data expected in 2027. A favorable arbitration outcome with Beam Therapeutics confirmed Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency, with an IND and/or CTA submission planned for the third quarter of 2026. The FDA granted Regenerative Medicine Advanced Therapy designation to PM359 in chronic granulomatous disease, and the company is engaging toward a potential BLA submission in the first half of 2027.
Prime Medicine, Inc. reported that an arbitration tribunal issued a final award resolving its dispute with Beam Therapeutics over their 2019 Collaboration and License Agreement. The tribunal declared that PM647, Prime Medicine’s development candidate for treating Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine’s contractual field and that the company did not breach the agreement. As a result, the tribunal denied Beam’s requests for damages and injunctive relief based on its breach allegations. The tribunal also denied the remaining claims brought by both Beam and Prime Medicine.
Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. Following this grant, he holds options on 75,000 shares.
The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders, provided he remains in continuous service with the company through that vesting date. This is a compensation-related, non‑market transaction.
Prime Medicine, Inc. director Jeffrey D. Marrazzo reported receiving a grant of stock options on June 5, 2026. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, held directly.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, provided he continues serving the company through that date. The options expire on June 5, 2036, and following this grant he holds 75,000 derivative securities of this type.
Prime Medicine director and 10% owner Robert Nelsen received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, all 75,000 underlying shares vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, assuming he continues to provide service to the company through that vesting date. This is a compensation-related award, not an open-market purchase or sale.
Prime Medicine director Kelly Michael Aaron received a new stock option grant that could convert into common shares in the future. The award covers 75,000 shares of common stock at an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, the option vests in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting, as long as Aaron continues serving the company through that vesting date. After this grant, Aaron holds stock options for 75,000 underlying shares directly.
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036.
The 75,000 options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, subject to Foster-Cheek’s continuous service. Following this grant, the filing shows holdings of 75,000 derivative securities, with no open‑market buys or sells reported.
Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, with all 75,000 options shown as held after this grant.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, as long as Chung continues to provide service to the company through that vesting date. The options expire on June 5, 2036 if not exercised.
Prime Medicine, Inc. director Thomas Cahill received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. They vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, assuming continuous service, leaving Cahill with 75,000 derivative shares after this award.